Clinical Trial Update: FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial [Phase 2]

View source ↗

Summary

Phase 2 PRTY Trial evaluating FDG-PET-guided metastasis-directed radiation therapy for metastatic hormone-sensitive prostate cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Prostate Cancer

Snippet

Sponsor: Northwestern University | Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Status: RECRUITING